News Releases

News and information from The Leukemia & Lymphoma Society

LLS and ASH Announce Collaboration Against Deadly Form of Leukemia

Rye Brook, NY; Washington, DC – June 20, 2016 - The Leukemia & Lymphoma Society (LLS) and the American Society of Hematology (ASH) are teaming up to raise awareness and provide education about the need for new treatments for acute myeloid leukemia (AML), one of the most deadly blood cancers that has not seen a change in the standard of care for more than 40 years. AML is a complex group of approximately 20 d...

New Research: Americans of Every Political Stripe are Unified in Support of Vice President Biden’s Moonshot to End Cancer

Rye Brook, NY, June 1, 2016 – While divisiveness rules many issues, there is strong agreement among Americans of different political persuasions when it comes to investing in the fight against cancer.  According to a new survey, Finding Cancer Cures, there is widespread support for the Moonshot to End Cancer initiative President Obama launched this year, as 82 percent of Americans polled want the next presiden...

Subaru and LLS Celebrate Gestures of Hope for Subaru Love Promise

Rye Brook, NY (May 31, 2016) – Subaru of America and The Leukemia & Lymphoma Society (LLS) announced a collaboration to provide much needed support and “warmth” to patients fighting cancer and their families in communities across the country.  During Subaru Loves to Care month this June, LLS and participating Subaru retailers across the country together will provide blankets and messages of hope to ...

LLS Applauds Approval of New Therapy for CLL Patients

Rye Brook, NY – April 12, 2016 – The approval of a new therapy for patients with a high-risk form of chronic lymphocytic leukemia (CLL) is welcome news for patients for whom there have been few other options, The Leukemia & Lymphoma Society (LLS) said today. The U.S. Food and Drug Administration has approved venetoclax (Venclexta ®) to treat patients with a rare subset of CLL in which a piece of chromosom...

Pages

Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: